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High-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) are strong predictors of
atherosclerosis. Statin-induced changes in the ratio of LDL-C to HDL-C (LDL-C/HDL-C) predicted atherosclerosis progression
betterthanLDL-CorHDL-Calone.However,thebestpredictorofsubclinicalatherosclerosisremainsunknown.Ourobjectivewas
to investigate this issue by measuring changes in carotid intima-media thickness (IMT). A total of 1,920 subjects received health
examinations in 1999, and were followed up in 2007. Changes in IMT (follow-up IMT/baseline IMT × 100) were measured by
ultrasonography.OurresultsshowedthatchangesinIMTaftereightyearsweresigniﬁcantlyrelatedtoHDL-C(inversely,P<0.05)
and to LDL-C/HDL-C ratio (P<0.05). When the LDL-C/HDL-C ratios were divided into quartiles, analysis of covariance showed
that increases in the ratio were related to IMT progression (P<0.05). This prospective study demonstrated the LDL-C/HDL-C
ratio is a better predictor of IMT progression than HDL-C or LDL-C alone.
1.Introduction
A low level of high-density lipoprotein cholesterol (HDL-C)
is a strong and independent predictor of cardiovascu-
lar disease [1–3]. Experimental studies have also shown
that increased levels of low-density lipoprotein cholesterol
(LDL-C) play a role in the development and progression of
atherosclerosis [3–5]. Moreover, previous studies reported
statin-induced changes in the ratio of LDL-C to HDL-C
(LDL-C/HDL-C ratio) predicted atherosclerosis progression
[6, 7]. It is, therefore, important to observe not only HDL-C
or LDL-C alone but also their ratio. However, it is not
known whether lipid levels alone or their ratio is more
useful clinically for predicting the progression of subclinical
atherosclerosis.
Elevated levels of LDL-C/HDL-C or apolipoprotein
(apo)B100/A-1ratioswerereportedinpatientswithcoronary
atherosclerosis [8–10]. It has been shown that a high LDL-
C/HDL-C ratio is a strong predictor of cardiovascular events
[6, 11]. However, whether a high LDL-C/HDL-C ratio is
a signiﬁcant predictor of carotid atherosclerotic burden
remains unclear due to a lack of data from a large number
of subjects. Although several investigators [12, 13]r e p o r t e d
that LDL-C/HDL-C ratio is related to IMT or carotid plaque
in cross-sectional studies or in relation to baseline data
in childhood, no large-scale prospective studies have been
done to in adults to evaluate whether elevated levels of
the LDL-C/HDL-C ratio is a more signiﬁcant predictor
of the progression of IMT than LDL-C or HDL-C alone.
Accordingly, we measured lipid proﬁles and employed high-
resolution ultrasonography to determine common carotid
IMT at baseline in 1,920 subjects of a community-based
cohort, and examined changes in IMT in a follow-up
examination 8 years later.2 Journal of Lipids
2. Methods
2.1. Study Subjects. A periodic epidemiological survey was
performed in 1999 in a small farming community in
Japan (a cohort of the Seven Countries Study) on the
island of Kyushu. As reported previously, the demographic
backgrounds of the subjects in this area are similar to
those of the Japanese general population [14]. The subjects’
medical history, especially past history of cerebro-cardio
vascular diseases, was ascertained in detail by a team of
physicians. IMT was measured by means of high-resolution
carotid ultrasonography in 1,920 subjects (794 men and
1,126 women) over the age of 40 years. Common carotid
IMT was measured by duplex ultrasonography (SSA-380A,
Toshiba) with a 10-MHz transducer in the sitting position.
Longitudinal B-mode images at the diastolic phase of the
cardiac cycle were recorded. The images were magniﬁed
and printed with a high-resolution line recorder (LSR-100A,
Toshiba). IMT was measured using ﬁne slide calipers at three
levels of the lateral and medial walls one to three centimeters
proximal to the carotid bifurcation. These six combined
near- and far-wall measurements were averaged. In our
laboratory, interobserver and intraobserver variabilities of
IMT were 3.8% and 4.2%, respectively (n = 30).
Eight years later, we performed a follow-up examination.
IMT was measured in the same manner as in the original
examination.Investigatorsatre-examinationwereblindedto
the participants’ clinical characteristics and to their baseline
IMT values. Changes in IMT were calculated as the value of
follow-up IMT divided by baseline IMT, and were expressed
as a percentage. Of 1,920 subjects in the original study,
baseline lipid proﬁles were missing in 164 subjects, and
follow-up IMT could not be performed in 300 subjects (183
had died, 73 refused the re-examination, 37 were lost to
follow-up, and 7 had moved). In the end, complete data sets
were available from 1,456 subjects, for a follow-up rate of
75.8%.
Informed consent was obtained from all subjects. The
study was approved by the Kurume University Ethics Com-
mittee.
2.2. Study Protocol. The subjects’ medical history, alcohol
intake, and smoking habits were ascertained by a question-
naire. Alcohol intake and smoking habits were classiﬁed
as current habitual use or not. Height and weight were
measured, and body mass index (BMI) was calculated as
weight (kg) divided by the square of height (m2) as an index
of obesity. Waist circumference was measured at the level
of the umbilicus in the standing position. Blood pressure
(BP) was measured in the right arm twice with a mercury
sphygmomanometer after subjects had rested in a supine
position for more than 5 minutes. The second BP with the
ﬁfth-phase diastolic pressure was used for analysis.
Blood was drawn from the antecubital vein for determi-
nations of glycosylated hemoglobin A1c (HbA1c), lipids pro-
ﬁles (total cholesterol, LDL-C, HDL-C, triglycerides (TG),
and remnant-like lipoprotein particle cholesterol (RLP-C),
and free fatty acid (FFA)) in the morning after 12-hour
fast. Fasting blood samples were centrifuged immediately
after collection. Serum total cholesterol, LDL-C, HDL-C,
TG, FFA, and creatinine were measured by enzymatic assay
method, and RLP-C was measured by an immunoseparation
technique using an immunoaﬃnity gel containing mono-
clonal antibodies to human apo B100 and apo A-1 [15]. Non-
HDL-C was calculated by subtracting HDL-C from total
cholesterol. Similarly, we evaluated ratios of proatherogenic
lipoprotein measurements, including total cholesterol to
HDL-C (TC/HDL-C), LDL-C to HDL-C (LDL-C/HDL-C),
TG to LDL-C (TG/LDL-C), and TG to HDL-C (TG/HDL-
C). HbA1c was measured by ion-exchange high-performance
liquid chromatography. All blood chemistry analyses were
performed at a commercial laboratory (The Kyodo Igaku
Laboratory, Fukuoka, Japan).
2.3. Statistical Analyses. Results were presented as mean ±
standard deviation (SD). Because of skewed distributions,
TG, RLP-C, and FFA were log-transformed before data anal-
yses; mean values, and upper and lower 95% conﬁdence lim-
its, were exponentiated and presented as geometric mean ±
SD, where the SD was approximated as the diﬀerence
between the exponentiated conﬁdence limits divided by
3.92, the value of SD in a 95% conﬁdence interval for
normally distributed data. Sex, smoking habits, alcohol
intake, hypertensive medication, diabetic medication, and
hyperlipidemic medication were used as dummy variables.
In order to investigate factors responsible for changes
in IMT after 8 years, multiple linear regression analyses
were performed with age, sex, and baseline IMT. The
mean changes in IMT levels stratiﬁed by quartiles of LDL-
C/HDL-C ratio were compared using analysis of covariance
(ANCOVA) adjusted for age, sex, baseline IMT, and lipid
lowering medications. Since subjects with a greater IMT
at baseline may exhibit increased changes in IMT, further
analysis was performed using the subjects with an IMT less
than 1.1mm at baseline. This subanalysis used the same
ANCOVA analysis as described above.
Statistical signiﬁcance was deﬁned as P<0.05. All anal-
yses were performed with the use of the SAS system (SAS
Institute Inc., Software 9.2, Cary, NC, USA).
3. Results
Demographic data for the 1,920 subjects at baseline in 1999
are presented in Table 1. As is apparent from the table,
the enrolled subjects had almost normal mean values of
risk factors and other variables. Table 2 shows the results
of univariable analysis performed for correlates of IMT
using multiple linear regression analysis adjusted for age
and sex. At baseline, there were signiﬁcant cross-sectional
relationships between IMT and systolic or diastolic BPs (P<
0.001), BMI (P<0.001), waist circumference (P<0.05),
total cholesterol (P<0.05), HDL-C (P<0.001; inversely),
LDL-C (P<0.001), total/HDL-C ratio (P<0.001), LDL-
C/HDL-C ratio (P<0.001), TG/HDL-C ratio (P<0.01),
RLP-C (P<0.05), and HbA1c (P<0.01). After adjusting for
age, sex, BMI, and smoking habits, multiple linear regression
analysis showed signiﬁcant relationships between IMT andJournal of Lipids 3
Table 1: Characteristics of subjects at baseline in 1999.
Men Women Total
N 794 1126 1920
Age, years 63.6 ±11.06 2 .1 ±11.06 2 .7 ±11.0
Systolic blood pressure, mmHg 135.7 ±21.6 131.7 ±21.4 133.4 ±21.6
Diastolic blood pressure, mmHg 81.0 ± 13.1∗ 76.9 ±11.47 8 .6 ±12.3
Body mass index, kg/m2 23.2 ±3.02 3 .0 ±3.22 3 .1 ±3.1
Waist, cm 81.6 ±8.67 3 .8 ±8.47 7 .0 ±9.3
IMT, mm 0.75 ±0.22∗∗ 0.67 ±0.18 0.70 ±0.20
Absolute diﬀerence of IMT, mm 0.03 ±0.02 0.04 ±0.01 0.04 ±0.01
Total cholesterol, mg/dL 188.8 ±32.8 207.4 ±33.8 199.8 ±34.6
HDL-C, mg/dL 51.6 ±15.45 7 .9 ±14.35 5 .8 ±14.0
LDL-C, mg/dL 118.1 ±31.2 128.5 ±30.3 124.2 ±31.0
Triglycerides†, mg/dL 105.6 ±2.7∗∗ 82.8 ±2.49 8 .5 ±2.6
Non-HDL-C, mg/dL 136.4 ±33.2∗∗ 149.3 ±33.8 144.0 ±34.2
LDL-C/HDL-C ratio 2.4 ±0.9∗∗ 2.3 ±0.82 .4 ±0.8
Total cholesterol/HDL-C ratio 3.82 ±1.14∗∗ 3.74 ±0.99 3.77 ±1.06
Triglycerides/HDL-C ratio† 2.07 ±0.05∗∗ 1.64 ±0.04 1.80 ±0.05
Triglycerides/LDL-C ratio† 0.92 ±0.02∗∗ 0.74 ±0.02 0.81 ±0.02
Free fatty acid†,m E q / L 0 .51 ±0.01 0.56 ±0.01 0.53 ±0.01
RLP-C†, mg/dL 3.52 ±0.09 3.47 ±0.09 3.49 ±0.09
HbA1c, % 5.2 ±0.85 .2 ±0.75 .2 ±0.8
Smoking, % 38.8 2.0 17.2
Alcohol intake, % 48.9 3.2 22.1
Hypertensive medication, % 20.5 19.0 19.6
Diabetic medication, % 3.9 2.6 3.1
Lipids lowering medication, % 2.4 6.4 4.7
∗P < 0.05, ∗∗P < 0.001, †Log-transformed values were used in analyses. IMT: intima-media thickness; HDL-C: high-density lipoprotein cholesterol; LDL-C:
low-density lipoprotein cholesterol; RLP-C: remnant-like particle cholesterol.
total cholesterol (P<0.05), HDL-C (P<0.001; inversely),
LDL-C (P<0.001), LDL-C/HDL-C ratio (P<0.0001),
TG/HDL-C ratio (P<0.01), and RLP-C (P<0.05).
In Table 3, multiple linear regression analysis revealed
that baseline systolic BP (P<0.01), BMI (P<0.05), waist
circumference (P<0.01), HDL-C (P<0.05; inversely),
TC/HDL-C ratio (P<0.05), LDL-C/HDL-C ratio (P<
0.05), and TG/LDL-C ratio (P<0.05; inversely) were
signiﬁcant predictors of IMT progression after 8 years, after
adjustments for age, sex, and baseline IMT. LDL-C/HDL-C
ratio in particular was more closely associated with outcome
than any of the other individual proatherogenic lipoprotein
parameters.
Figure 1(a) shows mean changes in IMT levels stratiﬁed
by quartiles of LDL-C/HDL-C ratio, compared by ANCOVA
adjusted for age, sex, baseline IMT, and lipid lowering
medications. Increased LDL-C/HDL-C ratios were related to
IMT progression (P = 0.007 for trend). Further analysis was
performed using the subjects with an IMT less than 1.1mm
at baseline (Figure 1(b)). This subanalysis also showed a
signiﬁcant linear trend between LDL-C/HDL-C ratio and
IMT progression.
In analyses using the receiver operating characteristic
(ROC) curve, an LDL-C to HDL-C ratio of 2.3 (area under
curve 0.552) showed the strongest association with IMT
progression(80.3%sensitivityand79.3%speciﬁcity,datanot
shown).
4. Discussion
This is the ﬁrst report of a general population or large-scale
epidemiological study focusing on the relationship between
LDL-C/HDL-C ratio and IMT progression.
4.1. Methodological Considerations. In this study, we eval-
uated changes in IMT by high-resolution carotid ultra-
sonography but did not measure plaques. It may have
been preferable to measure changes in plaques rather than
IMT. However, it is very diﬃcult to accurately estimate the
changes in plaques because of their complex morphology.
In contrast, the evaluation of IMT is relatively simple and
accurate. Furthermore, IMT, as an indicator of subclinical
atherosclerosis, has been shown to be a strong risk factor4 Journal of Lipids
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Figure 1: Relationship between LDL-C/HDL-C ratio and changes in IMT. (a) Data from 1,456 subjects was analyzed by ANCOVA adjusted
for age, sex, baseline IMT, and lipids lowering medication. (b) Data from 1,349 subjects with less than 1.1mm IMT at baseline was analyzed
by ANCOVA adjusted for age, sex, baseline IMT, and lipid lowering medications.
for cardiovascular events [16]. Measurement of IMT could
help to identify asymptomatic subjects with subclinical
atherosclerosiswhowouldbeneﬁtfromaggressivepreventive
measures.
With regard to composite variables that include proath-
erogenic lipoprotein measurements, data for direct compar-
isons are limited to studies based on the general population
[17, 18]. In the present study, some of the ratios and
the single measurements such as LDL-C, HDL-C, and
RLP-C were included in study variables. Although other
population-based studies [17, 18] included antiatherogenic
lipoprotein fraction ratios such as apo B/A-I, their main
target endpoint was cardiovascular events. Our objective was
to determine the best predictor of progression of subclinical
atherosclerosis, and we used changes in IMT as a surrogate
marker for atherosclerosis. As shown in Figure 1(b), since
the subjects with thicker IMT tend to exhibit relatively large
changes in IMT, a further analysis was performed using the
subjects with less than 1.1mm IMT at baseline. This type
of careful subanalysis may help us to better understand the
signiﬁcance of changes in IMT.
4.2. Predictors for Progression of IMT. A signiﬁcant associa-
tion between IMT and proatherogenic lipoprotein measure-
ments was shown in Table 2. Even in this cross-sectional
study, we found LDL-C/HDL-C ratio was the strongest
predictor. We observed the same result in our prospective
study, as shown in Table 3. Because age, male gender, and
baseline IMT are well-known signiﬁcant factors for the pro-
gression of IMT, we adjusted for them to determine factors
for progression of IMT. However, the present study showed
that the absolute diﬀerences (0.03mm versus 0.04mm) and
the percent diﬀerences (104.0% versus 105.9%) between
the IMT at baseline and during follow-up period did not
diﬀer signiﬁcantly between the two genders. Therefore, we
performed an additional analysis using 1,349 subjects with
an IMT less than 1.1mm at baseline (Figure 1(b)). The
results of our multiple linear regression analysis showed
that the LDL-C/HDL-C ratio was the strongest predictor
for IMT progression (β = 1.55453, P<0.05). Although
one prospective study [19] reported the predictive utility of
LDL/HDL ratio for carotid IMT in subjects using childhood
levels, ours is the ﬁrst large prospective study to conﬁrm
this result in a community-based cohort without apparent
cerebro-cardiovascular diseases.
Our data may suggest that elevated LDL/HDL ratio is
not just a marker of atherosclerosis but may play a causal
role in thepathogenesis ofhuman IMTprogression. Another
interesting issue to be clariﬁed is the cut-oﬀ values of LDL-
C/HDL-C for predicting IMT progression. One Japanese
investigator[20]hassuggestedthetargetindexforregression
of atherosclerosis should be less than 2.0 for primary
prevention and less than 1.5 for secondary prevention. Based
on the ROC curves, the cut-oﬀ point was 2.3 in this study.
The detailed analysis stratiﬁed by LDL-C/HDL-C quartiles
(Figures 1(a) and 1(b)) may conﬁrm this cut-oﬀ value.Journal of Lipids 5
Table 2: Association between IMT and variables at baseline in
multiple linear regression analysis adjusted for age and sex.
Variables β Standard error Probability
Systolic blood pressure 0.00158 0.0002 <0.01
Diastolic blood pressure 0.00145 0.0003 <0.01
Body mass index 0.00444 0.0013 0.01
Waist 0.00119 0.0005 0.01
Total cholesterol 0.00028 0.0001 0.02
HDL-C −0.00127 0.0003 <0.01
LDL-C 0.00053 0.0001 <0.01
Triglycerides∗ 0.00006 0.0001 0.23
Non-HDL-C 0.00049 0.0001 <0.01
LDL-C/HDL-C ratio 0.02930 0.0048 <0.01
Total cholesterol/HDL-C 0.02083 0.0037 <0.01
ratio
Triglycerides/HDL-C ratio∗ 0.02034 0.0062 <0.01
Triglycerides/LDL-C ratio∗ 0.00237 0.0078 0.76
Free fatty acid 0.00313 0.0075 0.68
RLP-C 0.01832 0.0073 0.01
HbA1c 0.01688 0.0052 <0.01
Smoking 0.00632 0.0120 0.60
Alcohol intake −0.02119 0.0114 0.06
∗Log-transformed were used for triglycerides, triglyceride/HDL-C ratio,
triglyceride/LDL-C ratio, free fatty acid, and RLP-C concentration. HDL-
C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein
cholesterol; RLP-C: remnant-like particle cholesterol.
4.3. Study Limitations. This study had some limitations.
First, the lack of biochemical measurements and medication
datainthefollowupisamajorlimitation.Second,wedidnot
measure total plaque area. Third, we only examined subjects
older than 40 years old. It would be interesting to determine
whether LDL-C/HDL-C ratio is a predictor of progression of
IMT of the carotid artery in subjects younger than 40 years
of age. Fourth, several pharmacological interventions have
beneﬁcial eﬀects on prevention of the progression of IMT
[21, 22]. However, because we have no data on medications
taken after the baseline examination, we cannot comment
on the question of whether such interventions have any
beneﬁcial eﬀects on IMT progression. Further studies are
needed to address this issue.
In conclusion, to our knowledge, this is the ﬁrst epi-
demiological report in a community cohort to show that
LDL-C/HDL-C ratio is a better predictor of carotid IMT
progression than HDL-C or LDL-C alone.
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Table 3: Relationship between 8-year changes in IMT and variables
in multiple linear regression analysis adjusted for age, sex, and
baseline IMT.
Variables β Standard error Probability
Systolic blood pressure 0.07764 0.0278 0.01
Diastolic blood pressure 0.01312 0.0464 0.78
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Non-HDL-C 0.02595 0.0156 0.10
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Triglycerides/HDL-C ratio∗ 0.80106 0.7886 0.31
Triglycerides/LDL-C ratio∗ −1.32504 0.9724 0.03
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